Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

6.7%

1 terminated/withdrawn out of 15 trials

Success Rate

92.9%

+6.4% vs industry average

Late-Stage Pipeline

53%

8 trials in Phase 3/4

Results Transparency

69%

9 of 13 completed trials have results

Key Signals

9 with results

Enrollment Performance

Analytics

Phase 3

5(35.7%)

Phase 1

3(21.4%)

Phase 4

3(21.4%)

Phase 2

2(14.3%)

Early Phase 1

1(7.1%)

14Total

Phase 3(5)

Phase 1(3)

Phase 4(3)

Phase 2(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials

NCT04467983Phase 4Active Not Recruiting

Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone

Role: collaborator

NCT04167163Phase 4Completed

Abaloparatide Before Total Knee Arthroplasty

Role: collaborator

NCT04626141Phase 4Withdrawn

Supracondylar Distal Femur Fractures and Abaloparatide

Role: collaborator

NCT04974723Completed

Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women

Role: lead

NCT04366726Phase 1Completed

Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Usability of Abaloparatide-solid Microstructured Transdermal System (sMTS) in Postmenopausal Women With Low Bone Mineral Density (BMD)

Role: lead

NCT03512262Phase 3Completed

Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)

Role: lead

NCT04064411Phase 3Completed

Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis

Role: lead

NCT04797728Early Phase 1Completed

Elacestrant in Preoperative Setting, a Window of Opportunity Study

Role: collaborator

NCT04663464Phase 1Completed

Study to Evaluate and Compare the PK Profiles of Abaloparatide-SC and Abaloparatide-sMTS in a Cohort of Healthy Men and Healthy Women.

Role: lead

NCT04936984Phase 1Completed

Study to Evaluate and Compare the Bioequivalence of Two Abaloparatide-sMTS Treatments in Healthy Women.

Role: lead

NCT03710889Phase 3Completed

Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption

Role: lead

NCT01657162Phase 3Completed

Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis

Role: lead

NCT01674621Phase 2Completed

Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis

Role: lead

NCT00542425Phase 2Completed

Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis

Role: lead

NCT01343004Phase 3Completed

Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women

Role: lead

All 15 trials loaded